HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malyak, M. Articles by Arend, W. P. Search for Related Content PubMed PubMed Citation Articles by Malyak, M. Articles by Arend, W. P.

The Differential Production of Three Forms of IL-1 Receptor Antagonist by Human Neutrophils and Monocytes¹

Mark Malyak^*, Michael F. Smith, Jr.^*,, Ashley A. Abel^*, Kenneth R. Hance^* and William P. Arend^2,*,

^* Division of Rheumatology, Department of Medicine, and Department of Immunology, University of Colorado Health Sciences Center, Denver, CO 80262

IL-1R antagonist (IL-1Ra) exists as three well-characterized isoforms. The 17-kDa secretory IL-1Ra (sIL-1Ra) and 18-kDa intracellular IL-1Ra (icIL-1RaI) arise by alternative transcription of the same IL-1Ra gene. The recently described 16-kDa intracellular IL-1Ra (icIL-1RaII) is formed by alternative translation initiation of sIL-1Ra mRNA. Transcription and translation of IL-1Ra isoforms were examined in LPS-stimulated human neutrophils and PBMC using RT-PCR, ELISA, and Western blot analysis. LPS stimulation of neutrophils resulted in elevated sIL-1Ra mRNA levels by 1 h, whereas icIL-1RaI mRNA remained undetectable through 22 h of culture. Extracellular glycosylated sIL-1Ra protein and intracellular icIL-1RaII were observed in LPS-stimulated neutrophils by 3 h of culture; no icIL-1RaI protein was detected by immunoblot. LPS stimulation of PBMC resulted in elevated sIL-1Ra mRNA levels by 1 h and detectable icIL-1RaI mRNA at 8 h of culture. LPS-stimulated PBMC demonstrated extracellular glycosylated sIL-1Ra protein and intracellular icIL-1RaII within 3 h of stimulation, whereas detection of icIL-1RaI protein was delayed until 15 h of culture. Subcellular localization experiments established that both icIL-1RaI and icIL-1RaII were present primarily within the cytoplasmic compartment, as expected by their lack of a signal peptide. These results demonstrate that although both LPS-stimulated neutrophils and PBMC synthesize sIL-1Ra and icIL-1RaII, only PBMC transcribe and translate icIL-1RaI. Furthermore, sIL-Ra transcription and translation (and translation of icIL-1RaII) are early events, whereas icIL-1RaI transcription in PBMC is delayed.

This article has been cited by other articles:

				A. S. Fahy, R. H. Clark, E. F. Glyde, and G. L. Smith Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence J. Gen. Virol., October 1, 2008; 89(10): 2377 - 2387. [Abstract] [Full Text] [PDF]

				N. K. Banda, C. Guthridge, D. Sheppard, K. S. Cairns, M. Muggli, D. Bech-Otschir, W. Dubiel, and W. P. Arend Intracellular IL-1 Receptor Antagonist Type 1 Inhibits IL-1-Induced Cytokine Production in Keratinocytes through Binding to the Third Component of the COP9 Signalosome J. Immunol., March 15, 2005; 174(6): 3608 - 3616. [Abstract] [Full Text] [PDF]

				L. R. Prince, L. Allen, E. C. Jones, P. G. Hellewell, S. K. Dower, M. K.B. Whyte, and I. Sabroe The Role of Interleukin-1{beta} in Direct and Toll-Like Receptor 4-Mediated Neutrophil Activation and Survival Am. J. Pathol., November 1, 2004; 165(5): 1819 - 1826. [Abstract] [Full Text] [PDF]

				H. L. Wilson, S. E. Francis, S. K. Dower, and D. C. Crossman Secretion of Intracellular IL-1 Receptor Antagonist (Type 1) Is Dependent on P2X7 Receptor Activation J. Immunol., July 15, 2004; 173(2): 1202 - 1208. [Abstract] [Full Text] [PDF]

				K. Isoda, M. Shiigai, N. Ishigami, T. Matsuki, R. Horai, K. Nishikawa, M. Kusuhara, Y. Nishida, Y. Iwakura, and F. Ohsuzu Deficiency of Interleukin-1 Receptor Antagonist Promotes Neointimal Formation After Injury Circulation, August 5, 2003; 108(5): 516 - 518. [Abstract] [Full Text] [PDF]

				V. M. Irikura, M. Lagraoui, and D. Hirsh The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor J. Immunol., July 1, 2002; 169(1): 393 - 398. [Abstract] [Full Text] [PDF]

				D. D. Hagaman, Y. Okayama, C. D'Ambrosio, C. Prussin, A. M. Gilfillan, and D. D. Metcalfe Secretion of Interleukin-1 Receptor Antagonist from Human Mast Cells after Immunoglobulin E-Mediated Activation and after Segmental Antigen Challenge Am. J. Respir. Cell Mol. Biol., December 1, 2001; 25(6): 685 - 691. [Abstract] [Full Text] [PDF]

				B. Canaud, V. Wizemann, F. Pizzarelli, R. Greenwood, G. Schultze, C. Weber, and D. Falkenhagen Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2181 - 2187. [Abstract] [Full Text] [PDF]

				R. Dewberry, H. Holden, D. Crossman, and S. Francis Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2394 - 2400. [Abstract] [Full Text] [PDF]

				W. P Arend and C. J Guthridge Biological role of interleukin 1 receptor antagonist isoforms Ann Rheum Dis, November 1, 2000; 59(90001): i60 - 64. [Abstract] [Full Text] [PDF]

				R. Horai, S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist-Deficient Mice J. Exp. Med., January 17, 2000; 191(2): 313 - 320. [Abstract] [Full Text] [PDF]

				M. Malyak, J. M. Guthridge, K. R. Hance, S. K. Dower, J. H. Freed, and W. P. Arend Characterization of a Low Molecular Weight Isoform of IL-1 Receptor Antagonist J. Immunol., August 15, 1998; 161(4): 1997 - 2003. [Abstract] [Full Text] [PDF]